Natera and Aveta Biomics Announce Strategic Partnership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Natera and Aveta Biomics announced a strategic partnership supporting AVTA 30-01, Aveta's global Phase 3 registrational clinical trial evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma. APG-157 is Aveta's first-in-class oral immunotherapy intended to expand the benefits of immunotherapy to both immune-cold and immune-hot tumors in patients with LA-HNSCC. APG-157 has received FDA Fast Track and Orphan Drug Designations for this indication. AVTA 30-01 builds upon previously reported Phase 2 clinical data of APG-157 monotherapy in demonstrating favorable safety, evidence of tumor-control, deep molecular responses, and encouraging event-free survival outcomes. The trial will incorporate serial Signatera testing to assess molecular residual disease and treatment response throughout therapy and follow-up. Circulating tumor DNA has emerged as one of the most promising approaches for detecting MRD and identifying recurrence earlier than conventional imaging alone. Approximately 826 patients are expected to be enrolled across North America, Europe, Asia-Pacific, and Australia. The study includes separate randomized cohorts for resectable and unresectable locally advanced disease, each with treatment and control arms, and Signatera will be a secondary endpoint. The trial is expected to begin enrollment in 2H'26.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to fall
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 283.800
Low
205.00
Averages
262.92
High
300.00
Current: 283.800
Low
205.00
Averages
262.92
High
300.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Signatera Test Shows Survival Benefits in Colorectal Cancer Patients
- Significant Survival Benefit: Among 298 patients with resected colorectal liver metastases, MRD-positive patients receiving adjuvant chemotherapy had a 48-month overall survival rate of 65.3%, significantly higher than the 32.9% in the observation group, highlighting the importance of the Signatera test in personalized treatment.
- Clear Prognostic Indicator: Post-surgical MRD positivity 2-10 weeks after surgery was strongly associated with worse survival outcomes, with hazard ratios of 4.82 for disease-free survival and 9.43 for overall survival in patients who received neoadjuvant chemotherapy, indicating MRD status as a crucial factor in treatment decisions.
- Broad Clinical Application: This study provides critical survival data for clinicians to identify which patients are most likely to benefit from adjuvant chemotherapy, further advancing the application of Signatera in personalized medicine.
- Robust Research Background: The findings were presented at the 2026 European Society for Medical Oncology Congress, emphasizing Natera's leadership in cell-free DNA and precision medicine, which is expected to drive further growth in the oncology sector.
See More
Natera and Aveta Partner for Phase 3 Clinical Trial of APG-157
- Strategic Partnership Initiated: Natera and Aveta Biomics have formed a strategic partnership to advance the AVTA 30-01 clinical trial, evaluating APG-157's efficacy in patients with locally advanced head and neck squamous cell carcinoma, with an expected enrollment of 826 patients across North America, Europe, Asia-Pacific, and Australia, showcasing a strong collaboration in the oncology field.
- Innovative Therapy Potential: APG-157, as a first-in-class oral immunotherapy, has received FDA Fast Track and Orphan Drug Designations, aiming to provide new treatment options for both immune-cold and immune-hot tumors, potentially transforming the treatment landscape for locally advanced head and neck cancer and improving patient survival rates.
- Molecular Testing Application: The AVTA 30-01 trial will incorporate Signatera testing to assess molecular residual disease (MRD) and treatment response, utilizing circulating tumor DNA (ctDNA) technology, which is expected to detect recurrences earlier than conventional imaging, further validating the positive results observed in the Phase 2 trial.
- Significant Market Demand: With a global annual incidence of approximately 950,000 for head and neck cancer, and recurrence remaining a major cause of mortality despite advancements in surgery, radiation, and immunotherapy, the successful development of APG-157 will help address this unmet medical need, enhancing the market positions of both Natera and Aveta.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Natera Partners with Eledon for Kidney Transplant Trial
- Strategic Partnership: Natera and Eledon have entered into a collaboration to integrate Natera's Prospera kidney transplant assessment test into Eledon's planned Phase 3 clinical trial, set to begin in late 2026, aimed at preventing organ rejection, highlighting a significant alliance in precision medicine.
- Exclusive Monitoring Tool: Under the agreement, Prospera will serve as the exclusive donor-derived cell-free DNA monitoring assay for the Phase 3 study, which is expected to enroll approximately 600 kidney transplant recipients across over 100 transplant centers globally, enhancing the trial's monitoring capabilities.
- Therapeutic Potential: Tegoprubart, a novel anti-CD40L antibody, has shown promising efficacy and safety in prior transplant studies, with Eledon developing this therapy to improve graft protection while reducing the toxicities associated with current immunosuppressants, thereby enhancing long-term outcomes.
- Innovative Monitoring Application: This collaboration marks the first use of Prospera as a surveillance tool in a large-scale therapeutic transplant study, providing an opportunity to assess allograft health through serial molecular monitoring while evaluating the impact of a new immunosuppression regimen, which holds significant clinical implications.
See More
JGRO Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: JGRO's 52-week low is $81.16 per share and the high is $99.73, with the last trade at $94.97, indicating that the stock is fluctuating near its high, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average provides investors with deeper insights into market trends and potential buying opportunities, enhancing their trading strategies.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade in 'units' rather than traditional shares, allowing investors to buy and sell these units, which enables ETFs to adapt flexibly to market demand changes.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows or outflows, allowing investors to assess the impact on underlying assets and make more informed investment decisions.
See More
Natera Partners with Eledon for Kidney Transplant Trial Using Prospera Test
- Partnership Agreement: Natera and Eledon have entered into a partnership to utilize Natera's Prospera test in Eledon's planned Phase 3 trial for the kidney transplant drug tegoprurbart, marking a strategic collaboration in the field of cell-free DNA testing.
- Market Reaction: Eledon Pharmaceuticals' shares rose 5.06% to $4.1605 in pre-market trading on Nasdaq, reflecting positive market sentiment towards the partnership, following a 0.25% increase in Wednesday's regular session.
- Trial Scale: The trial aims to enroll approximately 600 kidney transplant recipients across over 100 centers globally, set to commence in late 2026, indicating Eledon's expansion plans and market potential in the kidney transplant sector.
- Drug Background: Tegoprurbart is an anti-CD40L antibody being tested as an alternative to standard immunosuppressive drugs like tacrolimus, which carry toxicity risks, and this collaboration will aid in advancing the clinical validation of new therapies.
See More
Signatera Test Shows Survival Benefits in Colorectal Cancer Patients
- Significant Survival Benefit: Among 298 patients with resected colorectal liver metastases, MRD-positive patients receiving adjuvant chemotherapy had a 48-month overall survival rate of 65.3%, significantly higher than the 32.9% in the observation group, highlighting the importance of the Signatera test in personalized treatment.
- Clear Prognostic Indicator: Post-surgical MRD positivity 2-10 weeks after surgery was strongly associated with worse survival outcomes, with hazard ratios of 4.82 for disease-free survival and 9.43 for overall survival in patients who received neoadjuvant chemotherapy, indicating MRD status as a crucial factor in treatment decisions.
- Broad Clinical Application: This study provides critical survival data for clinicians to identify which patients are most likely to benefit from adjuvant chemotherapy, further advancing the application of Signatera in personalized medicine.
- Robust Research Background: The findings were presented at the 2026 European Society for Medical Oncology Congress, emphasizing Natera's leadership in cell-free DNA and precision medicine, which is expected to drive further growth in the oncology sector.
See More
Natera and Aveta Partner for Phase 3 Clinical Trial of APG-157
- Strategic Partnership Initiated: Natera and Aveta Biomics have formed a strategic partnership to advance the AVTA 30-01 clinical trial, evaluating APG-157's efficacy in patients with locally advanced head and neck squamous cell carcinoma, with an expected enrollment of 826 patients across North America, Europe, Asia-Pacific, and Australia, showcasing a strong collaboration in the oncology field.
- Innovative Therapy Potential: APG-157, as a first-in-class oral immunotherapy, has received FDA Fast Track and Orphan Drug Designations, aiming to provide new treatment options for both immune-cold and immune-hot tumors, potentially transforming the treatment landscape for locally advanced head and neck cancer and improving patient survival rates.
- Molecular Testing Application: The AVTA 30-01 trial will incorporate Signatera testing to assess molecular residual disease (MRD) and treatment response, utilizing circulating tumor DNA (ctDNA) technology, which is expected to detect recurrences earlier than conventional imaging, further validating the positive results observed in the Phase 2 trial.
- Significant Market Demand: With a global annual incidence of approximately 950,000 for head and neck cancer, and recurrence remaining a major cause of mortality despite advancements in surgery, radiation, and immunotherapy, the successful development of APG-157 will help address this unmet medical need, enhancing the market positions of both Natera and Aveta.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Natera Partners with Eledon for Kidney Transplant Trial
- Strategic Partnership: Natera and Eledon have entered into a collaboration to integrate Natera's Prospera kidney transplant assessment test into Eledon's planned Phase 3 clinical trial, set to begin in late 2026, aimed at preventing organ rejection, highlighting a significant alliance in precision medicine.
- Exclusive Monitoring Tool: Under the agreement, Prospera will serve as the exclusive donor-derived cell-free DNA monitoring assay for the Phase 3 study, which is expected to enroll approximately 600 kidney transplant recipients across over 100 transplant centers globally, enhancing the trial's monitoring capabilities.
- Therapeutic Potential: Tegoprubart, a novel anti-CD40L antibody, has shown promising efficacy and safety in prior transplant studies, with Eledon developing this therapy to improve graft protection while reducing the toxicities associated with current immunosuppressants, thereby enhancing long-term outcomes.
- Innovative Monitoring Application: This collaboration marks the first use of Prospera as a surveillance tool in a large-scale therapeutic transplant study, providing an opportunity to assess allograft health through serial molecular monitoring while evaluating the impact of a new immunosuppression regimen, which holds significant clinical implications.
See More
JGRO Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: JGRO's 52-week low is $81.16 per share and the high is $99.73, with the last trade at $94.97, indicating that the stock is fluctuating near its high, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average provides investors with deeper insights into market trends and potential buying opportunities, enhancing their trading strategies.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade in 'units' rather than traditional shares, allowing investors to buy and sell these units, which enables ETFs to adapt flexibly to market demand changes.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows or outflows, allowing investors to assess the impact on underlying assets and make more informed investment decisions.
See More
Natera Partners with Eledon for Kidney Transplant Trial Using Prospera Test
- Partnership Agreement: Natera and Eledon have entered into a partnership to utilize Natera's Prospera test in Eledon's planned Phase 3 trial for the kidney transplant drug tegoprurbart, marking a strategic collaboration in the field of cell-free DNA testing.
- Market Reaction: Eledon Pharmaceuticals' shares rose 5.06% to $4.1605 in pre-market trading on Nasdaq, reflecting positive market sentiment towards the partnership, following a 0.25% increase in Wednesday's regular session.
- Trial Scale: The trial aims to enroll approximately 600 kidney transplant recipients across over 100 centers globally, set to commence in late 2026, indicating Eledon's expansion plans and market potential in the kidney transplant sector.
- Drug Background: Tegoprurbart is an anti-CD40L antibody being tested as an alternative to standard immunosuppressive drugs like tacrolimus, which carry toxicity risks, and this collaboration will aid in advancing the clinical validation of new therapies.
See More
